<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540202</url>
  </required_header>
  <id_info>
    <org_study_id>QALE07</org_study_id>
    <nct_id>NCT00540202</nct_id>
  </id_info>
  <brief_title>Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children</brief_title>
  <acronym>QALE</acronym>
  <official_title>Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uganda Malaria Surveillance Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will test the hypothesis that there is a difference in effectiveness of oral quinine in
      comparison to artemether Lumefantrine in the treatment of uncomplicated malaria in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be designed as an open randomized effectiveness study assessing the
      parasitological and clinical cure rates and adherence to oral quinine monotherapy in
      comparison to artemether-Lumefantrine. We will also describe some of the adverse events to
      the two drugs.The measurements will include age, sex, weight, hemoglobin levels on days 0, 7,
      14 and 28, parasite density on days 0, 7, 14 and 28 and clinical examination findings.
      Adverse events will also be documented
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. PCR adjusted parasitological cure rate on day 28. 2. Clinical cure rates on day 28.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Fever clearance time assessed by self report. 2. Hemoglobin changes on day 0, 7, 14 and 28. 3. Safety profiles. 4. Adherence: measured by patient report and pill count on day 3 for the artemether-Lumefantrine group and day 7 for the quinine group.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">302</enrollment>
  <condition>Uncomplicated Malaria</condition>
  <arm_group>
    <arm_group_label>1.Oral quinine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Coartem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>artemether-lumefantrine</intervention_name>
    <description>Tablets taken twice daily for 3 days according to weight based guidelines.</description>
    <arm_group_label>2. Coartem</arm_group_label>
    <other_name>Coartem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral quinine</intervention_name>
    <description>Quinine tablets given at 10mg/kg 8 hourly for 7 days</description>
    <arm_group_label>1.Oral quinine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 6 and 59 months of age seen at the assessment centre during the study
             period

          2. With fever defined as axillary temperature ≥37.5 °C or history of fever in the past 24
             h

          3. With a microscopically confirmed monoinfection of Plasmodium falciparum

          4. Able to tolerate oral therapy,

          5. Whose parents/guardians have provided written informed consent.

        Exclusion Criteria:

          1. Children with a history of allergy to quinine, artemether-Lumefantrine or milk.

          2. Evidence of severe malaria.

          3. Residence at more than 20km from the health clinic.

          4. Evidence of a significant concomitant febrile illness that would require
             hospitalization or chronic medical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ambrose O Talisuna, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Uganda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Achan, MMed</last_name>
    <phone>+256-772-410183</phone>
    <email>achanj@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Kyabayinze, MSc</last_name>
    <phone>+256-772-744066</phone>
    <email>d.kyabayinze@malariaconsortium.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mulago National Referral Hospital</name>
      <address>
        <city>Kampala</city>
        <state>Central</state>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Achan, MMed</last_name>
      <phone>+256-772-410183</phone>
      <email>achanj@yahoo.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Maiteki, MD</last_name>
      <phone>+256-712-840449</phone>
      <email>cmaiteki@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Moses Kamya, MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P, Musabe J, Kyomugisha A, Guthmann JP. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004 Nov;71(5):525-30.</citation>
    <PMID>15569777</PMID>
  </reference>
  <reference>
    <citation>de Vries PJ, Bich NN, Van Thien H, Hung LN, Anh TK, Kager PA, Heisterkamp SH. Combinations of artemisinin and quinine for uncomplicated falciparum malaria: efficacy and pharmacodynamics. Antimicrob Agents Chemother. 2000 May;44(5):1302-8.</citation>
    <PMID>10770766</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2007</study_first_posted>
  <last_update_submitted>October 4, 2007</last_update_submitted>
  <last_update_submitted_qc>October 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2007</last_update_posted>
  <keyword>Effectiveness</keyword>
  <keyword>Oral quinine</keyword>
  <keyword>Coartem</keyword>
  <keyword>Uncomplicated malaria</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

